Aquestive 制药 AQST
$3.61 −$0.05 (-1.37%)
休市 · Nov 6, 8:10 pm ET · 最新盘后价 $3.60 -0.28%
开盘$3.71
昨收$3.66
当日区间$3.55 – $3.76
成交量4.14M
市值$453.73M
市盈率（TTM）–
股息率–
财报
财报日平均波动±7.7%近16次财报
收涨次数6 / 1638% 的概率
最佳反应+20.9%
最差反应-19.6%
每次财报后次日股价变动
| 季度 | 财报日期 | 时段 | 隐含波动 | 实际波动 | 较隐含波动 |
|---|---|---|---|---|---|
| 2026/Q2 | 11 Aug 2026 | After Market | ±14.7% | -4.08% | 符合区间 |
| 2026/Q1 | 13 May 2026 | After Market | ±9.1% | +14.53% | 超出定价预期 |
| 2025/Q4 | 4 Mar 2026 | After Market | ±16.6% | -2.52% | 符合区间 |
| 2025/Q3 | 5 Nov 2025 | After Market | ±15.7% | +2.17% | 符合区间 |
| 2025/Q2 | 11 Aug 2025 | After Market | ±34.6% | -2.07% | 符合区间 |
| 2025/Q1 | 12 May 2025 | After Market | ±18.6% | -19.65% | 超出定价预期 |
| 2024/Q4 | 5 Mar 2025 | After Market | ±24.4% | -7.53% | 符合区间 |
| 2024/Q3 | 4 Nov 2024 | After Market | ±23.3% | -7.67% | 符合区间 |
| 2024/Q2 | 6 Aug 2024 | After Market | ±17.3% | +0.88% | 符合区间 |
| 2024/Q1 | 7 May 2024 | After Market | ±20.3% | -8.73% | 符合区间 |
| 2023/Q4 | 5 Mar 2024 | None | ±50.0% | +20.05% | 符合区间 |
| 2023/Q3 | 6 Nov 2023 | After Market | ±73.0% | +4.91% | 符合区间 |
| 2023/Q2 | 8 Aug 2023 | Pre Market | ±24.4% | -5.37% | 符合区间 |
| 2023/Q1 | 2 May 2023 | After Market | ±121.6% | +20.86% | 符合区间 |
| 2022/Q4 | 7 Mar 2023 | After Market | ±200.0% | +0.00% | 符合区间 |
| 2022/Q3 | 1 Nov 2022 | After Market | ±203.4% | -1.81% | 符合区间 |
"隐含波动"指财报发布前期权市场定价的预期波幅。"波动"指财报发布后首个交易日的股价变化。
基本面
最新报告季度：Q2, ended Jun 2026
营收$13.82M+38.1% YoY
营业利润-$8.22M+27.7% YoY
净利润-$22.86M-68.8% YoY
摊薄每股收益-$0.18-28.6% YoY
自由现金流-$9.65M-20.3% YoY
经营现金流-$9.44M
营收，近8个季度
净利润，近8个季度
盈利能力与资产负债表
毛利率67.0%
营业利润率-97.5%
净利率-144.6%
资产收益率-69.3%
流动比率7.19
负债/资产比率142.8%
现金及投资$98.49M
总负债$58.21M
净现金（净负债）$40.28M
暂无评论——快来第一个聊聊 AQST。
登录后参与讨论。